Novartis lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker’s Sandoz generics unit saw rising international demand for its biosimilar copies of blockbuster drugs made by rivals.
Powered by WPeMatico